Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01518309 · ClinicalTrials.gov registry record · Phase 2
An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
A Phase 2 study, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT01518309 is a Phase 2 study that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 39 participants.
The verdict
NCT01518309, a Phase 2 study, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).
Interventions
- DRUG pimavanserin tartrate (ACP-103)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2004-11-17 |
| Est. Completion | 2013-05-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01518309
The ClinicalTrials.gov registry entry for NCT01518309 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pimavanserin tartrate (ACP-103) is the first listed.
NCT01518309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01518309 about?
NCT01518309 is a clinical study titled "An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients". This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).
What is the current status of trial NCT01518309?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2004-11-17. Estimated completion is 2013-05-02.
What interventions are being tested in trial NCT01518309?
The interventions under investigation include: pimavanserin tartrate (ACP-103) (DRUG).
Who is sponsoring clinical trial NCT01518309?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.